CALIFORNIA HEART CENTER FOUNDATION: Form 990, tax year 2016

View the entire original 990 at ProPublica ↗

Organization
CALIFORNIA HEART CENTER FOUNDATION (EIN 95-4772979)
Tax period
2016-01-01 to 2016-12-31
Filed
2017-11-13
IRS object ID
201743179349308904
Schema version
2016v3.0
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2017-11-13T19:42:55-06:00ReturnTs
Tax Period End2016-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN346565596PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1ERNST & YOUNG US LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line118101 VON KARMAN AVENUE SUITE 1700AddressLine1Txt
CityIRVINECityNm
State AbbreviationCAStateAbbreviationCd
ZIP92612ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2016-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN954772979EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1CALIFORNIA HEART CENTER FOUNDATIONBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlCALIBusinessNameControlTxt
Phone3102488327PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line18536 WILSHIRE BOULEVARD 3RD FLOORAddressLine1Txt
CityBEVERLY HILLSCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90211ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonJON KOBASHIGAWA MDPersonNm
Person TitlePRESIDENTPersonTitleTxt
Phone3102488327PhoneNum
Signature2017-11-13SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonKARA ADAMSPreparerPersonNm
PTINP00023315PTIN
Phone9497942300PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

FieldValueIRS element (for citing)
I Pv4 Address192.231.86.239IPv4AddressTxt
FieldValueIRS element (for citing)
IP2017-11-13IPDt
IP Tm17:01:45IPTm
IP TimezonePSIPTimezoneCd
Filing License TypePFilingLicenseTypeCd
At Submission Creation Device IdEA7D571819A2DDFF3FA87BB29D436B4703CBDB69AtSubmissionCreationDeviceId
At Submission Filing Device IdA21C8ECFBAEEE1A023FC812FE8CE0E929F59BD7FAtSubmissionFilingDeviceId
FieldValueIRS element (for citing)
Tax2016TaxYr
Build TS2017-02-10 21:41:12ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerJON KOBASHIGAWA MDPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line18536 WILSHIRE BOULEVARD 3RD FLOORAddressLine1Txt
CityBEVERLY HILLSCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90211ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$1,830,128GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.CALHEART.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2000FormationYr
Legal Domicile StateCALegalDomicileStateCd
Activity Or MissionPROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE.ActivityOrMissionDesc
Voting Members Governing Body12VotingMembersGoverningBodyCnt
Voting Members Independent7VotingMembersIndependentCnt
Total Employee0TotalEmployeeCnt
Total Volunteers7TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$1,784,016PYContributionsGrantsAmt
CY Contributions Grants$1,531,356CYContributionsGrantsAmt
PY Program Service Revenue$146,199PYProgramServiceRevenueAmt
CY Program Service Revenue$298,766CYProgramServiceRevenueAmt
PY Investment Income$1,031PYInvestmentIncomeAmt
CY Investment Income$6CYInvestmentIncomeAmt
PY Other Revenue$0PYOtherRevenueAmt
CY Other Revenue$0CYOtherRevenueAmt
PY Total Revenue$1,931,246PYTotalRevenueAmt
CY Total Revenue$1,830,128CYTotalRevenueAmt
PY Grants And Similar Paid$0PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$0CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$1,686,274PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$1,422,984CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$0CYTotalFundraisingExpenseAmt
PY Other Expenses$420,440PYOtherExpensesAmt
CY Other Expenses$408,790CYOtherExpensesAmt
PY Total Expenses$2,106,714PYTotalExpensesAmt
CY Total Expenses$1,831,774CYTotalExpensesAmt
PY Revenues Less Expenses-$175,468PYRevenuesLessExpensesAmt
CY Revenues Less Expenses-$1,646CYRevenuesLessExpensesAmt
Total Assets BOY$133,728TotalAssetsBOYAmt
Total Assets EOY$58,893TotalAssetsEOYAmt
Total Liabilities BOY$197,995TotalLiabilitiesBOYAmt
Total Liabilities EOY$124,806TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY-$64,267NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY-$65,913NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$1,494,424ExpenseAmt
Revenue$298,766RevenueAmt
DescTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2016: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "A CASE-BASED GUIDE TO PULMONARY HYPERTENSION CME" (PASADENA, CA): THIS 1-DAY CME PROGRAM TOOK PLACE ON SATURDAY, JANUARY 23RD, 2016 AT THE WESTIN PASADENA. THE PROGRAM, DESIGNED FOR PRIMARY CARE PHYSICIANS, PULMONOLOGISTS, RHEUMATOLOGISTS, CARDIOLOGISTS AND OTHER AFFILIATED STAFF INTERESTED IN THE PREVENTION AND MANAGEMENT OF PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION DREW 73 PARTICIPANTS FROM ACROSS SOUTHERN CALIFORNIA. NINE EXPERT FACULTY SPOKE ON THE LATEST DIAGNOSTIC AND THERAPEUTIC ADVANCES FOR PATIENTS WITH PH/PAH WITH DIDACTIC LECTURES, A SERIES OF CASE PRESENTATIONS, AND AUDIENCE PARTICIPATION. OVERALL THE PROGRAM WAS VERY WELL RECEIVED. * "CUTTING EDGE OF TRANSPLANTATION (CEOT)", FEBRUARY 25TH - 27TH, 2016 (PHOENIX, ARIZONA): THIS MEETING, PLANNED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, FEATURED A SPECIAL "HEART TRACK" THAT WAS CHAIRED BY DR. JON KOBASHIGAWA AND SPONSORED BY THE CEDARS-SINAI HEART INSTITUTE. FOCUSED ON THE THEME OF "RESOLVING THE ORGAN SHORTAGE", THE HEART TRACK FEATURED 5 DEDICATED SESSIONS OVER THREE DAYS ON ISSUES AND CHALLENGES FACING THE CARDIOTHORACIC COMMUNITY, INCLUDING PENDING POLICY CHANGES TO U.S. HEART ALLOCATION AND INNOVATIONS IN THE MANAGEMENT OF DONOR HEARTS. WITH DR. KOBASHIGAWA'S LEADERSHIP, THE HEART TRACK FEATURED A FACULTY OF LEADING EXPERTS IN THE FIELD AND ATTRACTED THE HIGHEST ATTENDANCE FROM THE CARDIOTHORACIC COMMUNITY SINCE THE INCEPTION OF THE CEOT MEETING. * "A CONSENSUS CONFERENCE ON THE MANAGEMENT OF ANTIBODIES IN HEART TRANSPLANTATION", APRIL 25TH, 2016 (WASHINGTON, DC): THIS INTERNATIONAL CONFERENCE, PLANNED IN COORDINATION WITH THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION, WAS DESIGNED TO PROVIDE A FORUM FOR AN IN-DEPTH DISCUSSION AMONG THE LEADING EXPERTS IN THE FIELD, INCLUDING CLINICIANS, PATHOLOGISTS AND IMMUNOLOGISTS. THE CONFERENCE SERVED AS A FIRST STEP IN DEVELOPING NEEDED GUIDELINES FOR THE ASSESSMENT AND TREATMENT OF PATIENTS WITH CIRCULATING ANTIBODIES BOTH PRE AND POST HEART TRANSPLANTATION, TO IMPROVE OUTCOMES AND MINIMIZE REJECTION COMPLICATIONS. ATTENDED BY 104 PHYSICIANS FROM 16 COUNTRIES AND REPRESENTING 73 TRANSPLANT CENTERS WORLDWIDE, THE CONFERENCE GENERATED A ROBUST DISCUSSION AND HELPED TO IDENTIFY A PATHWAY TO THE DEVELOPMENT OF GUIDELINES. RESULTS OF THE CONFERENCE WERE PRESENTED AT THE ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS AND A PUBLICATION OF CONFERENCE RESULTS IS CURRENTLY PENDING.* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM" (CULVER CITY, CA): THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, JUNE 3RD, 2016. TWENTY-ONE FACULTY SPEAKERS COVERED TOPICS RELATED TO THE PREVENTION AND MANAGEMENT OF HEART FAILURE, HEART TRANSPLANT EVALUATION, POST-TRANSPLANT CARE AND SURGICAL OPTIONS IN HEART FAILURE. THE PROGRAM DREW 201 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS. (MEETING SPONSOR: JON KOBASHIGAWA, MD) * "NEW INSIGHTS INTO THE IMPACT OF DONOR HLA SPECIFIC AND NON-HLA SPECIFIC ANTIBODIES IN SOLID ORGAN GRAFT OUTCOME" (LOS ANGELES, CA): THIS 1-DAY SYMPOSIUM ON ANTIBODIES IN SOLID ORGAN TRANSPLANTATION TOOK PLACE ON FRIDAY, SEPTEMBER 9TH, 2016. TEN FACULTY SPEAKERS COVERED TOPICS RELATED TO THE TESTING, MONITORING AND TREATMENT OF ANTIBODIES IN SOLID ORGAN TRANSPLANTATION. THE PROGRAM DREW 98 ATTENDEES CONSISTING OF CLINICIANS, PATHOLOGISTS, IMMUNOLOGISTS, FELLOWS AND ALLIED HEALTH WHO WORK IN THE AREA OF SOLID ORGAN TRANSPLANTATION. THE PROGRAM WAS EXTREMELY WELL RECEIVED. * "OPTIMAL CARE & NEW THERAPIES IN ADVANCED HEART DISEASE" (COSTA MESA, CA): THIS ONE-DAY SYMPOSIUM ON ADVANCED HEART DISEASE WAS HELD ON OCTOBER 29TH, 2016 AT THE WESTIN SOUTH COAST PLAZA. THE PROGRAM FEATURED PRESENTATIONS ON TOPICS RELATED TO THE DIAGNOSIS AND TREATMENT OF HEART FAILURE, TRANSPLANTATION, MECHANICAL CIRCULATORY SUPPORT AND PULMONARY HYPERTENSION. THE PROGRAM WAS ATTENDED BY 58 PEOPLE, INCLUDING A NUMBER OF COMMUNITY CARDIOLOGISTS IN THE LOCAL AREA.* "NIH INVESTIGATOR MEETING" (NEW ORLEANS) NOVEMBER 11TH, 2016: THIS ONE-DAY MEETING TOOK PLACE IN TANDEM WITH THE AMERICAN HEART ASSOCIATION'S ANNUAL MEETING AND IN COLLABORATION WITH CO-INVESTIGATORS AT MGH AND MT. SINAI. THE MEETING GATHERED 34 POTENTIAL SITE INVESTIGATORS TO DISCUSS PROTOCOL DEVELOPMENT FOR AN NIH GRANT SUBMISSION FOR A PROJECT INVESTIGATING THE EARLY ADDITION OF IL-6 SIGNALING BLOCKADE TO CONVENTIONAL IMMUNOSUPPRESSION IN THE EARLY POST-TRANSPLANT PERIOD TO DIMINISH PRO-INFLAMMATORY, INNATE AND ADAPTIVE B CELL RESPONSES FOLLOWING HEART TRANSPLANTATION.* HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED THE FOLLOWING VISITING PHYSICIANS:DR. TOBIA DEUSE, UNIVERSITY OF CALIFORNIA, SAN FRANCISCODR. SHADI DAOUD, HEALTHCARE PARTNERS OF NEVADADR. BINOY JOHN, MIOT INTERNATIONAL HOSPITAL, CHENNAI, INDIAJENNIFER BALLARD-HERNANDEZ, NP, VA MEDICAL CENTER, LONG BEACHDARREL TERRY, CEO, NEWARK BETH ISRAEL MEDICAL CENTERAMY MOITOZA, NP, SCRIPPSJENNIFER NOWACZYK, NP, SCRIPPSRUTH KUO, NP, SCRIPPSJULIAN EIGNER, NP, SCRIPPS* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO EIGHT STUDENTS FOR THE SUMMER OF 2016. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WILL BE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES:JAMES T. KWAN: UNIVERSITY OF CONNECTICUT (UNDERGRAD)KAYCEE CHING: UC BERKELEY (UNDERGRAD)LAUREN ARAKAWA: CALIFORNIA STATE POLYTECHNIC UNIVERSITY, POMONA (UNDERGRAD)JENNIFER KREMS: AMHERST COLLEGE (UNDERGRAD)KRISTEN YABUNO: UC IRVINE (UNDERGRAD)KEITH T. NISHIHARA: UC BERKELEY (UNDERGRAD)MICHAEL HASHIMOTO: UCLA (UNDERGRAD)FRANK KEVIN LIOU: DREXEL UNIVERSITY (1ST YEAR MED STUDENT)OLIVIA DING: TULANE UNIVERSITY (1ST YEAR MED STUDENT)CLINICAL RESEARCH:THIS SECTION WILL BE FORMATTED BY TITLE; PRINCIPAL INVESTIGATOR (PI); STATUS; SPONSOR.A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (CEP-41750) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; DAVID CHANG, MD; ENROLLING; TEVA PHARMACEUTICALSA MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL BPS-314D-MR ADDED-ON TO TREPROSTINIL, INHALED (TYVASO) IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; ENROLLING; LUNG BIOTECHNOLOGY, INC.Desc
Total Program Service Expenses$1,494,424TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Temp Or Permanent Endowments0TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other Liabilities0ReportOtherLiabilitiesInd
Include FIN48 Footnote0IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt0IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign Activities0ForeignActivitiesInd
More Than5000 K To Org0MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising Activities0FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To Organizations0GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With Officer Ent0BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri0DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded Entity0DisregardedEntityInd
Related EntityYes (1)RelatedEntityInd
Related Organization Ctrl EntYes (1)RelatedOrganizationCtrlEntInd
Transaction With Control Ent0TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document20IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (1)BackupWthldComplianceInd
Employee0EmployeeCnt
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo Contributions0QuidProQuoContributionsInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members12GoverningBodyVotingMembersCnt
Independent Voting Member7IndependentVotingMemberCnt
Family Or Business RlnYes (1)FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or StockholdersYes (1)MembersOrStockholdersInd
Election Of Board MembersYes (1)ElectionOfBoardMembersInd
Decisions Subject To ApprovaYes (1)DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn Body0Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower Policy0WhistleblowerPolicyInd
Document Retention Policy0DocumentRetentionPolicyInd
Compensation Process CEO0CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1DEBBIE BOTTENBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone3104238473PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line115821 VENTURA BLVD STE 520AddressLine1Txt
CityENCINOCityNm
State AbbreviationCAStateAbbreviationCd
ZIP91436ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (15 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtHighest Compensated EmployeeHighestCompensatedEmployeeInd
JON KOBASHIGAWA MD
PRESIDENT2.000.00Yes (X)Yes (X)$0$0$0
KEENAN BEHRLE
CHAIRPERSON2.000.00Yes (X)Yes (X)$0$0$0
JAMES HAMILTON
SECRETARY2.000.00Yes (X)Yes (X)$0$0$0
THOMAS D GORDON
CFO1.0065.00Yes (X)Yes (X)$0$629,294$157,990
MICHELE HAMILTON MD
DIRECTOR2.000.00Yes (X)$0$0$0
RICHARD B JACOBS
DIRECTOR1.0061.00Yes (X)$0$1,218,884$303,262
JOSEPH O LAMPE
DIRECTOR2.000.00Yes (X)$0$0$0
EDUARDO MARBAN MD
DIRECTOR1.0060.00Yes (X)$0$2,320,711$203,405
LAURENCE MARTON MD
DIRECTOR2.000.00Yes (X)$0$0$0
ARTHUR J OCHOA
DIRECTOR1.0065.00Yes (X)$0$1,001,700$63,438
WILLIAM OUCHI PHD
DIRECTOR2.000.00Yes (X)$0$0$0
EDWARD PRUNCHUNAS
DIRECTOR1.0065.00Yes (X)$0$1,541,844$361,892
ERIC N MARTON
FORMER PRESIDENT30.0030.00Yes (X)$0$154,565$3,756
CHRISTINE SUMBI
VICE PRESIDENT40.000.00Yes (X)$0$177,050$21,775
PHYLLIS KATZ
EXECUTIVE ASSISTANT40.000.00$0$108,256$27,796Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$0TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$7,152,304TotReportableCompRltdOrgAmt
Total Other Compensation$1,143,314TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K0IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd
Cntrct Rcvd Greater Than100 K0CntrctRcvdGreaterThan100KCnt
Related Organizations$1,531,356RelatedOrganizationsAmt
Total Contributions$1,531,356TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDescBusinessBusinessCdTotal Revenue ColumnTotalRevenueColumnAmtRelated Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt
EDUCATIONAL PROGRAMS611430$273,312$273,312
CULTURAL PROGRAMS611710$25,454$25,454
FieldValueIRS element (for citing)
Total Program Service Revenue$298,766TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$6TotalRevenueColumnAmt
Exclusion$6ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,830,128TotalRevenueColumnAmt
Related Or Exempt Func Income$298,766RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$6ExclusionAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$286,041TotalAmt
Management And General$286,041ManagementAndGeneralAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$932,910TotalAmt
Program Services$932,910ProgramServicesAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$52,056TotalAmt
Program Services$52,056ProgramServicesAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$69,295TotalAmt
Program Services$69,295ProgramServicesAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$82,682TotalAmt
Program Services$82,682ProgramServicesAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$4,065TotalAmt
Program Services$4,065ProgramServicesAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$54,896TotalAmt
Program Services$38,427ProgramServicesAmt
Management And General$16,469ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$7,920TotalAmt
Program Services$7,128ProgramServicesAmt
Management And General$792ManagementAndGeneralAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$34,278TotalAmt
Program Services$34,278ProgramServicesAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$8,044TotalAmt
Program Services$8,044ProgramServicesAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$212,298TotalAmt
Program Services$201,683ProgramServicesAmt
Management And General$10,615ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$2,849TotalAmt
Program Services$2,849ProgramServicesAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmt
MEALS AND ENTERTAINMENT$69,881$46,448$23,433
DUES & SUBSCRIPTIONS$6,833$6,833
MOVING/STORAGE$3,944$3,944
TELEPHONE$1,302$1,302

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$2,480TotalAmt
Program Services$2,480ProgramServicesAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$1,831,774TotalAmt
Program Services$1,494,424ProgramServicesAmt
Management And General$337,350ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$47,646BOYAmt
EOY$48,209EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$486BOYAmt
EOY$6,886EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$107,678LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$103,880LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$6,647BOYAmt
EOY$3,798EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$78,949BOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$133,728BOYAmt
EOY$58,893EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$180,995BOYAmt
EOY$124,806EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$17,000BOYAmt
EOY$0EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$197,995BOYAmt
EOY$124,806EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY-$64,267BOYAmt
EOY-$65,913EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY-$64,267BOYAmt
EOY-$65,913EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$133,728BOYAmt
EOY$58,893EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss-$1,646ReconcilationRevenueExpnssAmt
Other Changes In Net Assets$0OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS Audited0FSAuditedInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,445,229CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,357,431CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,514,534CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,784,016CurrentTaxYearMinus1YearAmt
Current Tax Year$1,531,356CurrentTaxYearAmt
Total$7,632,566TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,445,229CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,357,431CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,514,534CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,784,016CurrentTaxYearMinus1YearAmt
Current Tax Year$1,531,356CurrentTaxYearAmt
Total$7,632,566TotalAmt
FieldValueIRS element (for citing)
Public Support Total170$7,632,566PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$12,225CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$8,138CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$5,075CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,031CurrentTaxYearMinus1YearAmt
Current Tax Year$6CurrentTaxYearAmt
Total$26,475TotalAmt
FieldValueIRS element (for citing)
Total Support$7,659,041TotalSupportAmt
Gross Receipts Rltd Activities$615,840GrossReceiptsRltdActivitiesAmt
Public Support CY1700.99650PublicSupportCY170Pct
Public Support PY1700.99390PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule D IRS990ScheduleD

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$70,594OtherCostOrOtherBasisAmt
Depreciation$66,796DepreciationAmt
Book Value$3,798BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$37,084OtherCostOrOtherBasisAmt
Depreciation$37,084DepreciationAmt
Book Value$0BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$3,798TotalBookValueLandBuildingsAmt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (1)SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments0AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
THOMAS D GORDON
CFO$0$312,770$0$187,947$0$128,577$0$131,249$0$26,741$0$787,284$0$0
RICHARD B JACOBS
DIRECTOR$0$649,091$0$353,238$0$216,555$0$286,927$0$16,335$0$1,522,146$0$0
EDUARDO MARBAN MD
DIRECTOR$0$1,470,656$0$323,081$0$526,974$0$168,550$0$34,855$0$2,524,116$0$0
ARTHUR J OCHOA
DIRECTOR$0$574,330$0$284,655$0$142,715$0$29,189$0$34,249$0$1,065,138$0$0
EDWARD PRUNCHUNAS
DIRECTOR$0$794,056$0$377,165$0$370,623$0$335,871$0$26,021$0$1,903,736$0$0
ERIC N MARTON
FORMER PRESIDENT$0$106,232$0$40,000$0$8,333$0$0$0$3,756$0$158,321$0$0
CHRISTINE SUMBI
VICE PRESIDENT$0$157,459$0$19,254$0$337$0$12,574$0$9,201$0$198,825$0$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINE 3THE PRESIDENT IS COMPENSATED BY A RELATED ORGANIZATION. PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B.
PART I, LINE 4BTHE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING OFFICERS AND DIRECTORS RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2016. THOMAS D. GORDON 120,883 RICHARD B. JACOBS 164,337 EDUARDO MARBAN, MD 297,145 ERIC N. MARTON 8,276 ARTHUR J. OCHOA 124,109 EDWARD PRUNCHUNAS 299,972

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (10 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART III, LINE 4A(CONTINUED) A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECT DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; PFIZER A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; STUDY START-UP; UNITED THERAPEUTICS A PHASE 3 MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTRSC IN PATIENTS WITH TRANSTHYRETIN (TTR) MEDIATED FAMILIAL AMYLOIDOTIC CARDIOMYOPATHY (FAC); JIGNESH PATEL, MD, PHD; ENROLLMENT COMPLETE; ALNYLAM PHARMACEUTICALS A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE 20MG OR 80MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM); JIGNESH PATEL, MD, PHD; STUDY START-UP; PFIZER A PHASE 3, PLACEBO CONTROLLED DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE(INO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH); ANTOINE HAGE, MD; STUDY START-UP; BELLEROPHON PULSE TECHNOLOGIES LLC A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS); BABAK AZARBAL, MD; STUDY START-UP; DALCOR PHARMA UK LTD A PHASE III, INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL WORSENING STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION RECEIVING BACKGROUND ORAL MONOTHERAPY; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS A PROSPECTIVE, RANDOMIZED, CONTROLLED, UNBLINDED, MULTI-CENTER CLINICAL TRIAL TO EVALUATE THE HEARTWARE VENTRICULAR ASSIST DEVICE SYSTEM FOR DESTINATION THERAPY OF ADVANCED HEART FAILURE; JAIME MORIGUCHI, MD; ENROLLING; HEARTWARE, INC. A PROSPECTIVE, SINGLE ARM, MULTI-CENTER CLINICAL STUDY IN COLLABORATION WITH THE INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT (INTERMACS) TO EVALUATE THE THORACOTOMY IMPLANT TECHNIQUE OF THE HEARTWARE HVAD SYSTEM IN PATIENTS WITH ADVANCED HEART FAILURE; FRANCISCO ARABIA, MD; ENROLLING; HEARTWARE, INC. A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; ANTOINE HAGE, MD; STUDY START-UP; REATA PHARMACEUTICALS, INC. ADVANCED HEART DISEASE BIOBANK; ROBIN SHAW, MD; ENROLLING; CSMC ADVANCED HEART DISEASE REGISTRY; JON KOBASHIGAWA, MD; ENROLLING; CSMC AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE; ANTOINE HAGE, MD; STUDY START-UP; UNITED THERAPEUTICS AN OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION - A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310; ANTOINE HAGE, MD; ENROLLING; UNITED THERAPEUTICS BIOMARKERS OF PRIMARY GRAFT DYSFUNCTION AFTER CARDIAC TRANSPLANTATION; JON KOBASHIGAWA, MD; STUDY START-UP; COLUMBIA UNIVERSITY CARDIOMEMS HF SYSTEM POST APPROVAL STUDY; LAWRENCE CZER, MD; ENROLLING; ST. JUDE MEDICAL CELL-FREE DNA AND ANTIBODY-MEDIATED REJECTION IN A COHORT OF SENSITIZED HEART TRANSPLANT PATIENTS; JON KOBASHIGAWA, MD; ENROLLING; CSMS/CAREDX, INC. DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROARRAYS IN HEART TRANSPLANTATION, A MULTICENTER STUDY; JON KOBASHIGAWA, MD; ENROLLING, UNIVERSITY OF ALBERTA EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS; A SINGLE CENTER SURVEY STUDY; JON KOBASHIGAWA, MD; ENROLLING; CSMC HDL LEVELS AND CARDIAC ALLOGRAFT VASCULOPATHY (CAV); JON KOBASHIGAWA, MD; ENROLLING; CSMC HOME ECG MONITORING TO DETECT ALLOGRAFT REJECTION FOLLOWING HEART TRANSPLANTATION; JON KOBASHIGAWA, MD; ENROLLMENT COMPLETE; UCSF/NIH INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT; FRANCISCO ARABIA, MD; ENROLLING; UAB/NIH INTERNATIONAL TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR PRESERVING AND ASSESSING EXPANDED CRITERIA DONOR HEARTS FOR TRANSPLANTATION; FARDAD ESMAILIAN, MD; ENROLLING; TRANSMEDICS, INC. OBSERVATIONAL REVIEW OF CLINICAL OUTCOMES IN HEART FAILURE PATIENTS UNDERGOING BARIATRIC SURGERY; MICHELE HAMILTON, MD; ENROLLING; CSMC OUTCOMES ALLOMAP REGISTRY (OAR) STUDY; JON KOBASHIGAWA, MD; ENROLLING; CAREDX, INC. PULMONARY HYPERTENSION POST-LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION; JAIME MORIGUCHI, MD; ENROLLING; ACTELION PHARMACEUTICALS REGISTRY EVALUATION OF VITAL INFORMATION FOR VADS IN AMBULATORY LIFE; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UNIVERSITY OF MICHIGAN RISK STRATIFICATION PRIOR TO TANDEM ORTHOTOPIC HEART AND STEM CELL TRANSPLANT IN PATIENTS WITH SYSTEMIC AMYLOIDOSIS; JON KOBASHIGAWA, MD; ENROLLING; CSMC TANDEMHEART EXPERIENCES AND METHODS; DANNY RAMZY, MD, PHD; STUDY START-UP; CARDIACASSIST, INC. THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL; JIGNESH PATEL, MD, PHD; ENROLLING, ALEXION PHARMACEUTICALS THE MEDICAL ARM OF MECHANICAL CIRCULATORY SUPPORT (MEDAMACS) STUDY; MICHELLE KITTLESON, MD, PHD; ENROLLMENT COMPLETE; UAB/NIH US-BASED, OBSERVATIONAL, DRUG REGISTRY OF OPSUMIT (MACITENTAN) NEW USERS IN CLINICAL PRACTICE; ANTOINE HAGE, MD; ENROLLING; ACTELION PHARMACEUTICALS
FORM 990, PART IV, LINE 12THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/16 AND 6/30/17 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/16.
FORM 990, PART VI, SECTION A, LINE 2LAURENCE MARTON, MD, DIRECTOR AND ERIC MARTON, FORMER PRESIDENT HAVE A FAMILY RELATIONSHIP.
FORM 990, PART VI, SECTION A, LINE 6CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7ACEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7BRESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) SUBJECT TO SECTION 5.08, APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION.
FORM 990, PART VI, SECTION B, LINE 11BTHE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM.
FORM 990, PART VI, SECTION B, LINE 12CCONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.
FORM 990, PART VI, SECTION B, LINE 15BTHE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES.
FORM 990, PART VI, SECTION C, LINE 19THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (5 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxtDirect Controlling NADirectControllingNACdControlled OrganizationControlledOrganizationIndBusiness Name Line1DirectControllingEntityName/BusinessNameLine1Txt
CEDARS-SINAI MEDICAL CENTER
8700 BEVERLY BOULEVARDLOS ANGELESCA90048951644600HEALTHCARECA501(C)(3)LINE 3N/A0
CEDARS-SINAI MEDICAL CARE FOUNDATION
200 N ROBERTSON BOULEVARD 101BEVERLY HILLSCA90211954457756PROVISION OF MEDICAL CARE, TEACHING AND RESEARCHCA501(C)(3)LINE 12A, IYes (1)CEDARS-SINAI MEDICAL CENTER
KERLAN-JOBE ORTHOPAEDIC FOUNDATION
6801 PARK TERRACELOS ANGELESCA90045954707606EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINECA501(C)(3)LINE 7Yes (1)CEDARS-SINAI MEDICAL CARE FOUNDATION
SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN
2020 SANTA MONICA BLVD 4TH FLRSANTA MONICACA90404954789926EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONSCA501(C)(3)PFYes (1)CEDARS-SINAI MEDICAL CARE FOUNDATION
CFHS HOLDINGS INC
4650 LINCOLN BLVDMARINA DEL REYCA90292201645949HEALTHCARECA501(C)(3)LINE 3Yes (1)CEDARS-SINAI MEDICAL CENTER

Id Related Org Txbl Partnership IdRelatedOrgTxblPartnershipGrp (7 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdDirect Controlling NADirectControllingNACd
ENDOSCOPY CENTER OF SANTA MONICA LLC
12400 WILSHIRE BLVD STE 100LOS ANGELESCA90025113652210ENDOSCOPIES AND RELATED PROCEDURESCAN/A
ISS ASC HOLDINGS LLC
27271 LAS RAMBLAS STE 350MISSION VIEJOCA92691471890805INVESTMENT IN HEALTHCARE SERVICESCAN/A
DEL REY SURGERY INVESTORS LLC
11150 SANTA MONICA BLVD STE 700LOS ANGELESCA90025364756208INVESTMENT IN AMBULATORY SURGERY CENTERDEN/A
DEL REY SURGERY CENTER LLC
27271 LAS RAMBLAS STE 350MISSION VIEJOCA92691462305372OPERATOR OF AMBULATORY SURGERY CENTERCAN/A
CEDARS-SINAI BH ASC LLC
200 N ROBERTSON BLVD 101BEVERLY HILLSCA90211812266744HOLDING COMPANYCAN/A
CS-BH ASC HOLDINGS LLC
200 N ROBERTSON BLVD 101BEVERLY HILLSCA90211812246488HOLDING COMPANYCAN/A
INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC
8500 W 110TH STOVERLAND PARKKS66210263738893SPINE AND ORTHOPEDIC INSTITUTEDEN/A

Id Related Org Txbl Corp Tr IdRelatedOrgTxblCorpTrGrp (3 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdDirect Controlling NADirectControllingNACdEntity TypeEntityTypeTxtControlled OrganizationControlledOrganizationInd
OPTIMATRIX HEALTH SOLUTIONS INC
6500 WILSHIRE BLVD 9TH FLRLOS ANGELESCA90048954522779INFORMATION SYSTEMSCAN/ACYes (1)
CENTINELA FREEMAN HOLDINGS INC
4650 LINCOLN BLVDMARINA DEL REYCA90292593811890MEDICAL OFFICE BUILDING AND GROUND LEASE LESSORCAN/ACYes (1)
OTOHARMONICS CORPORATION
411 SW 6TH AVEPORTLANDOR97204461119421HEALTHCARE PRODUCT DEVELOPMENTDEN/ACYes (1)
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts Rylts0ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org0GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgYes (1)GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org0LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org0LoansOrGuaranteesFromOthOrgInd
Div Related Organization0DivRelatedOrganizationInd
Asset Sale To Other Org0AssetSaleToOtherOrgInd
Asset Purchase From Other Org0AssetPurchaseFromOtherOrgInd
Asset Exchange0AssetExchangeInd
Rental Of Facilities To Oth Org0RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org0RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org0PerformOfServicesForOthOrgInd
Perform Of Services By Other Org0PerformOfServicesByOtherOrgInd
Sharing Of FacilitiesYes (1)SharingOfFacilitiesInd
Paid Employees SharingYes (1)PaidEmployeesSharingInd
Reimbursement Paid To Other OrgYes (1)ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org0ReimbursementPaidByOtherOrgInd
Transfer To Other Org0TransferToOtherOrgInd
Transfer From Other Org0TransferFromOtherOrgInd

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.